Readoutin 135d
Almirall, S.A. — Lebrikizumab
Phase 3 primary completion: A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Dermatitis, Atopic
Readoutin 135d
Phase 3 primary completion: A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.